Ontario Sets Conditions for Out-of-Country Funding of Some Drug-Administration Services
A new Ontario regulation spells out when certain drug-administration services received outside Canada can qualify for provincial funding, including a narrow exception for temporary drug unavailability and urgent travel.
In this article & details
Ontario has amended its public drug-insurance regulation to set out when certain drug-administration services received outside Canada may be considered insured. The change, made October 6, 2026, concerns services consisting primarily of administering a drug. Ontario says the amendment clarifies a policy it has followed since 2011; it is not a general promise to reimburse medicines or treatment obtained abroad.
What the regulation says
Ontario Regulation 326/26 adds a pathway to Regulation 552 for a service consisting primarily of drug administration. The service must be identical or equivalent to one that could be performed in Ontario; the drug and its administration must be publicly funded in Ontario, in whole or in part, for a person in the same medical circumstances; and the drug must be temporarily unavailable in Ontario. In addition, the delay in obtaining it must make travel outside Canada necessary to avoid death or medically significant, irreversible tissue damage.
These conditions are cumulative. The regulation does not say that a patient can choose out-of-country care simply because it is faster, more convenient or available at a preferred site. Nor does the amendment itself determine whether a particular drug, service, patient or trip qualifies. Patients and clinicians should seek confirmation from the Ministry before relying on coverage.
Transition for prior approvals
The amendment includes a transition provision for services that had already received written prior approval on or before October 6 under the previous version of the regulation. Those services are deemed to be insured services under the amended rules. Patients with an existing approval should retain the written decision and confirm any remaining requirements with the Ministry or their care team.
The amendment is specific to Ontario’s public drug-insurance framework. It does not change other provinces’ plans, private insurance contracts or the clinical standards used to decide which treatment is appropriate. The regulatory text is the controlling source for the conditions and transition rule.
What pharmacists and care teams can do
For pharmacy teams, the key practical issue is helping patients distinguish an eligibility rule from a coverage confirmation. A treatment may be clinically appropriate without meeting the statutory funding conditions, and the existence of an exception does not guarantee approval in an individual case. Documentation of the drug’s availability, the patient’s circumstances, the proposed equivalent Ontario service and any written authorization may be important to a review.
Practice guidance for pharmacists
- When a patient asks about out-of-country drug administration, clarify that this rule applies to a narrow class of services and only within Ontario’s public plan.
- Review the exact criteria in Ontario Regulation 552, as amended by O. Reg. 326/26; do not infer eligibility from the fact that a service is publicly funded in Ontario.
- Encourage patients and prescribers to obtain written Ministry confirmation before travel or treatment, rather than relying on an informal interpretation.
- Document relevant information about temporary Ontario drug unavailability, the patient’s medical circumstances and the urgency described by the treating clinician.
- For an approval issued before October 6, retain the written approval and verify how the transition provision applies to the specific service.
- Refer borderline eligibility or reimbursement questions to the Ontario Ministry; do not promise coverage or substitute the regulation for individualized clinical advice.
What to watch
The amendment gives a formal regulatory description of the circumstances Ontario identifies for this kind of out-of-country funding. Any further guidance about applications, documentation or administration should be checked against current Ministry direction and the regulation itself.
Primary sources
